PHARM-BIO SERV INC - PBSV STOCK NEWS

Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving various industries including pharmaceuticals, announced a revenue decline for the three and six months ending April 30, 2024. Revenues were $2.4 million and $4.8 million, respectively, marking a decrease of $2.2 million and $4.0 million compared to the same periods last year. The company reported a net loss of $0.2 million and $0.5 million for these periods, compared to net income of $0.4 million and $0.8 million in the previous year. Despite these setbacks, the company is investing in new client relationships and global events to foster growth and stability in the future.

Pharma-Bio Serv, Inc. reported a decrease in revenues for the quarter ended January 31, 2024, with approximately $2.4 million in revenues and a net loss of approximately $270,700. The company aims to achieve sustainable growth and profitability through planned investments in business development infrastructure and resources for fiscal year 2024.

Pharma-Bio Serv, Inc. announced a decrease in revenues for the year ended October 31, 2023, but an improvement in net income. The company's overall gross profit improved by 4.6 percentage points compared to last year. The CEO highlighted the strategy of exploiting opportunities in new markets and pursuing robust opportunities in targeted markets to achieve external growth and maximize shareholder value.

Pharma-Bio Serv, Inc. (PBSV) announces approval of Special Dividend of $0.075 per share for Shareholders

Pharma-Bio Serv reports increase in net income and gross profit margin for Q3 2023. Revenues decrease compared to last year.

Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported revenue of approximately $4.2 million for the quarter ending January 31, 2023, marking a decrease of $0.8 million year-over-year. However, net income rose to $0.4 million, an increase of $0.1 million compared to the previous year. The CEO, Mr. Sanchez, emphasized the strategic focus on more profitable markets, resulting in improved gross profit percentages. The company operates in markets including Puerto Rico, the US, Europe, and Latin America, providing regulatory compliance consulting services across various industries.

Pharma-Bio Serv (OTCQB:PBSV) has announced a Special Dividend of $0.075 per share, payable on or about April 14, 2023. This dividend is for shareholders of record as of the close of business on March 29, 2023. The company offers consulting services in regulatory compliance to various industries, including pharmaceuticals and biotechnology, mainly in Puerto Rico, the United States, Europe, and Latin America. The announcement reflects the company's commitment to returning value to its shareholders.

Pharma-Bio Serv (OTCQB:PBSV), a consulting firm in regulatory compliance, announced its partnership with ACP Capital Markets LLC for investment banking and M&A advisory services. This collaboration is aimed at strategically growing the company through potential acquisitions and enhancing shareholder value. CEO Victor Sanchez expressed optimism about working with ACP, highlighting their M&A expertise. Pharma-Bio Serv's services span across the pharmaceutical and biotechnology sectors, serving markets in Puerto Rico, the U.S., Europe, and Latin America. The company emphasizes regulatory compliance consulting, supported by a skilled global team.